1995
DOI: 10.1177/009286159502900326
|View full text |Cite
|
Sign up to set email alerts
|

International Harmonization of Regulatory Requirements for Average Bioequivalence and Current Issues in Individual Bioequivalence

Abstract: International harmonization of regulatory requirements for average bioequivalence has made major progress during the last years, particularly with regard to the bioequivalence range and statistical analysis. The multiplicative model and hence the logarithmic transformation of the primary extent and rate characteristics A UC and C,, and-consistent with this-the bioequivalence range of (0.80, 1. 25) are now accepted by all major health authorities including the European Committee for Proprietary Medicinal Produc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1999
1999
2017
2017

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(2 citation statements)
references
References 16 publications
0
2
0
Order By: Relevance
“…Consistency was accepted where both duplicate sample determination were ≤20% CV for each trace and heavy metal investigated. The percentage CV criteria were based on the upper limit of acceptable analytical precision, and within the permissible statistical window for bioequivalence assessment [17][18][19]. Table 1 reflects the Ginseng and Hypoxis (African potato) products investigated (Table 1).…”
Section: Discussionmentioning
confidence: 99%
“…Consistency was accepted where both duplicate sample determination were ≤20% CV for each trace and heavy metal investigated. The percentage CV criteria were based on the upper limit of acceptable analytical precision, and within the permissible statistical window for bioequivalence assessment [17][18][19]. Table 1 reflects the Ginseng and Hypoxis (African potato) products investigated (Table 1).…”
Section: Discussionmentioning
confidence: 99%
“…The pro®les are then usually compared using summary measures. Area under the curve (AUC) is generally regarded as being the most important measure and there is international regulatory agreement 22 that trials should be analysed by showing that the 90% con®dence interval (CI) for the ratio of the AUCs should lie between the limits 80% and 125%. (Usually this has been done by analysing log-AUC using a linear model.)…”
Section: Bioequivalence Studiesmentioning
confidence: 99%